A060590 Stock Overview
Provides various pharmaceutical products in South Korea and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for A060590 from our risk checks.
CTCBIO Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩7,360.00 |
| 52 Week High | ₩12,280.00 |
| 52 Week Low | ₩6,050.00 |
| Beta | 0.42 |
| 11 Month Change | -2.65% |
| 3 Month Change | -7.77% |
| 1 Year Change | -36.88% |
| 33 Year Change | -27.84% |
| 5 Year Change | -0.54% |
| Change since IPO | 44.35% |
Recent News & Updates
Shareholder Returns
| A060590 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 7.1% | 2.9% | 0.3% |
| 1Y | -36.9% | 15.9% | -0.04% |
Return vs Industry: A060590 underperformed the KR Pharmaceuticals industry which returned 15.9% over the past year.
Return vs Market: A060590 underperformed the KR Market which returned -0% over the past year.
Price Volatility
| A060590 volatility | |
|---|---|
| A060590 Average Weekly Movement | 7.3% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in KR Market | 12.1% |
| 10% least volatile stocks in KR Market | 3.5% |
Stable Share Price: A060590 has not had significant price volatility in the past 3 months.
Volatility Over Time: A060590's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 241 | Mingoo Lee | www.ctcbio.com |
CTCBIO Inc. provides various pharmaceutical products in South Korea and internationally. The company offers animal and human pharmaceuticals; feed additives and ingredients; and functional food products. It also provides cardiovascular, gastrointestinal, osteoporosis, antibiotic, smoking cessation, antifungal and antiviral, antiepileptic, allergic rhinitis, dermatology and genito-urinory, allergic rhinitis and antihistamine, neuropsychiarty, intestinal disorders, X-ray, diabetes, anti-inflammatory and arthritis, and harmones, as well as CTC covid-19 IgM/IgG combo test, a quick antibody test kit on covid-19.
CTCBIO Inc. Fundamentals Summary
| A060590 fundamental statistics | |
|---|---|
| Market cap | ₩175.97b |
| Earnings (TTM) | -₩16.15b |
| Revenue (TTM) | ₩134.35b |
1.3x
P/S Ratio-10.9x
P/E RatioIs A060590 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A060590 income statement (TTM) | |
|---|---|
| Revenue | ₩134.35b |
| Cost of Revenue | ₩89.23b |
| Gross Profit | ₩45.11b |
| Other Expenses | ₩61.27b |
| Earnings | -₩16.15b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -675.63 |
| Gross Margin | 33.58% |
| Net Profit Margin | -12.02% |
| Debt/Equity Ratio | 38.4% |
How did A060590 perform over the long term?
See historical performance and comparison